Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors
-
Published:2021-01-18
Issue:3
Volume:39
Page:803-811
-
ISSN:0167-6997
-
Container-title:Investigational New Drugs
-
language:en
-
Short-container-title:Invest New Drugs
Author:
Meneses-Lorente Georgina,Bentley Darren,Guerini Elena,Kowalski Karey,Chow-Maneval Edna,Yu Li,Brink Andreas,Djebli Nassim,Mercier Francois,Buchheit Vincent,Phipps Alex
Abstract
SummaryBackground: Entrectinib is an oral, CNS-active, potent inhibitor of tyrosine receptor kinases A/B/C, tyrosine kinase ROS proto-oncogene 1, and anaplastic lymphoma kinase approved for use in patients with solid tumors. We describe 3 clinical studies, including one investigating the single/multiple dose pharmacokinetics of entrectinib in patients and two studies in healthy volunteers investigating the absorption/distribution/metabolism/excretion (ADME) of entrectinib, its relative bioavailability, and effect of food on pharmacokinetics. Methods: The patient study is open-label with dose-escalation and expansion phases. Volunteers received entrectinib (100–400 mg/m2, and 600–800 mg) once daily with food in continuous 28-day cycles. In the ADME study, volunteers received a single oral dose of [14C]entrectinib 600 mg. In the third study, volunteers received single doses of entrectinib 600 mg as the research and marketed formulations in the fasted state (Part 1), and the marketed formulation in the fed and fasted states (Part 2). Entrectinib and its major active metabolite M5 were assessed in all studies. Results: Entrectinib was absorbed in a dose-dependent manner with maximum concentrations at ~4 h postdose and an elimination half-life of ~20 h. Entrectinib was cleared mainly through metabolism and both entrectinib and metabolites were eliminated mainly in feces (minimal renal excretion). At steady-state, the M5-to-entrectinib AUC ratio was 0.5 (with 600 mg entrectinib research formulation in patients). The research and marketed formulations were bioequivalent and food had no relevant effect on pharmacokinetics. Conclusions: Entrectinib is well absorbed, with linear PK that is suitable for once-daily dosing, and can be taken with or without food.
Funder
Ignyta F. Hoffmann-La Roche
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference11 articles.
1. Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68(9):3077–3080; discussion 3080. https://doi.org/10.1158/0008-5472.CAN-07-3293 2. Weinstein IB, Joe AK (2006) Mechanisms of disease: oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3(8):448–457. https://doi.org/10.1038/ncponc0558 3. Shaw AT, Engelman JA (2013) ALK in lung cancer: past, present, and future. J Clin Oncol 31(8):1105–1111. https://doi.org/10.1200/JCO.2012.44.5353 4. Patel MR, Bauer TM, Liu SV, Drilon AE, Wheler JJ, Shaw AT, Farago AF, Ou S-HI, Luo D, Yeh L, Hornby Z, Senderowicz AM, Lim J (2015) STARTRK-1: phase 1/2a study of entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol 33(15_suppl):2596–2596. https://doi.org/10.1200/jco.2015.33.15_suppl.2596 5. Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG (2017) Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor Entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov 7(4):400–409. https://doi.org/10.1158/2159-8290.CD-16-1237
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|